VERACYTE, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
VERACYTE, INC. (VCYT) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $2.97 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-02-26
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.97M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.72M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.50M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.08M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $2.97M 10-K · filed 2026-02-26 |
| 2024-12-31 | $3.72M 10-K · filed 2026-02-26 |
| 2023-12-31 | $4.50M 10-K · filed 2026-02-26 |
| 2022-12-31 | $4.08M 10-K · filed 2025-02-28 |
| 2021-12-31 | $3.76M 10-K · filed 2024-02-29 |
| 2020-12-31 | $2.70M 10-K · filed 2023-03-01 |
| 2019-12-31 | $2.25M 10-K · filed 2022-02-28 |
| 2018-12-31 | $1.03M 10-K · filed 2021-02-22 |
| 2017-12-31 | $2.07M 10-K · filed 2020-02-25 |
| 2016-12-31 | $2.85M 10-K · filed 2019-02-25 |
| 2015-12-31 | $1.82M 10-K · filed 2018-02-27 |
| 2014-12-31 | $826.00K 10-K · filed 2017-03-01 |
| 2013-12-31 | $313.00K 10-K · filed 2016-03-14 |
| 2012-12-31 | $154.00K 10-K · filed 2015-03-25 |
| 2011-12-31 | $50.00K 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| BIODESIX INC (BDSX) | United States | $0.312B |